Education
About Us
Working with TipRanks
Follow Us
Pacira (PCRX)
:PCRX
Earnings Data
Report Date
Feb 19, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.91Last Year’s EPS
0.91Same Quarter Last Year
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved manufacturing efficiencies, and significant pipeline expansion. However, some challenges were noted with Zilretta's slower-than-expected sales growth and discount impacts from new GPO agreements affecting pricing. Elective procedure market growth was also described as sluggish.Company Guidance
Revenue Growth
Year-over-year revenues increased by 6%, driven by strong performance from EXPAREL and iovera. EXPAREL demand increased with year-over-year volumes up approximately 9%, marking the highest quarterly growth in over 3 years.
Manufacturing and Gross Margin
Improved manufacturing efficiencies and gross margins supported an increase in full-year guidance. Non-GAAP gross margins improved to 82% in the third quarter from 78% last year.
Pipeline Expansion
Clinical pipeline expanded with the in-licensing of AMT-143, a novel long-acting formulation of bupivacaine. The company also reported progress in its Phase II study of PCRX-201 for osteoarthritis of the knee.
Market Access and Coverage
The company is ahead of plan to surpass the full-year goal of 100 million covered lives across commercial and government payers. Approximately 60 million commercial lives now have access to EXPAREL via separate reimbursement.
Cash Flow and Shareholder Returns
Significant operating cash flow and a strong balance sheet enable investments in new growth initiatives. The company executed an additional $50 million in share repurchases during the quarter.
PCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $21.10 | $22.05 | +4.50% |
Aug 05, 2025 | $22.54 | $22.40 | -0.62% |
May 08, 2025 | $24.91 | $25.12 | +0.84% |
Feb 27, 2025 | $25.38 | $24.05 | -5.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pacira (PCRX) report earnings?
Pacira (PCRX) is schdueled to report earning on Feb 19, 2026, Before Open (Confirmed).
What is Pacira (PCRX) earnings time?
Pacira (PCRX) earnings time is at Feb 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PCRX EPS forecast?
PCRX EPS forecast for the fiscal quarter 2025 (Q4) is 0.91.